Renal and Red Marrow Dosimetry in Peptide Receptor Radionuclide Therapy: 20 Years of History and Ahead (original) (raw)
A dosimetry procedure for organs-at-risk in 177Lu peptide receptor radionuclide therapy of patients with neuroendocrine tumours
Nick Reynaert
Physica Medica
View PDFchevron_right
The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy
Grace Kong
European Journal of Nuclear Medicine and Molecular Imaging, 2012
View PDFchevron_right
Clinical Study Kidney Dosimetry in 177Lu and 90Y Peptide Receptor Radionuclide Therapy: Influence of Image Timing, Time-Activity Integration Method, and Risk Factors
G. Pedroli
2016
View PDFchevron_right
4-Step Renal Dosimetry Dependent on Cortex Geometry Applied to 90Y Peptide Receptor Radiotherapy: Evaluation Using a Fillable Kidney Phantom Imaged by 90Y PET
stephan walrand
Journal of Nuclear Medicine, 2010
View PDFchevron_right
Kidney dosimetry in ¹⁷⁷Lu and ⁹⁰Y peptide receptor radionuclide therapy: influence of image timing, time-activity integration method, and risk factors
E. Grassi
BioMed research international, 2013
View PDFchevron_right
In Vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy
Mark Konijnenberg
PloS one, 2017
View PDFchevron_right
Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapy
Felix Mottaghy
Medical Physics, 2012
View PDFchevron_right
Reducing the number of CTs performed to monitor personalized dosimetry during peptide receptor radionuclide therapy (PRRT)
Faozi Artoul
EJNMMI Physics, 2018
View PDFchevron_right
Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
Anne Arveschoug
EJNMMI Physics
View PDFchevron_right
Dosimetry in Peptide radionuclide receptor therapy: a review
Marta Cremonesi
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2006
View PDFchevron_right
Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management
Amichay Meirovitz
EJNMMI Physics
View PDFchevron_right
Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using [177Lu-[DOTA0, Tyr3]-octreotate
Erick Mora Ramirez
EJNMMI Research
View PDFchevron_right
Quantitative Imaging for Targeted Radionuclide Therapy Dosimetry - Technical Review
stefaan vandenberghe
Theranostics, 2017
View PDFchevron_right
Between the Scylla and Charybdis of peptide radionuclide therapy: hitting the tumor and saving the kidney
Otto Boerman
European Journal of Nuclear Medicine and Molecular Imaging, 2001
View PDFchevron_right
A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
Monica Celli
Journal of Visualized Experiments
View PDFchevron_right
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
Marta Cremonesi
European Journal of Nuclear Medicine and Molecular Imaging, 2011
View PDFchevron_right
Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study
Francois-Alexandre Buteau
European Journal of Nuclear Medicine and Molecular Imaging, 2017
View PDFchevron_right
Summary and Perspectives on Kidney Dose–Response to Radionuclide Therapy
Barry Wessels
Cancer Biotherapy & Radiopharmaceuticals, 2004
View PDFchevron_right
Radiation Dose Distribution in Human Kidneys by Octreotides in Peptide Receptor Radionuclide Therapy
Roelf Valkema, Marion Jong
2000
View PDFchevron_right
The impact of PET and SPECT on dosimetry for targeted radionuclide therapy
Sven-erik Strand, Myriam Monsieurs, Sauli Savolainen, Glenn Flux
Zeitschrift für medizinische Physik, 2006
View PDFchevron_right
{"__content__"=>"Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy.", "sup"=>{"__content__"=>"90"}}
Thomas O'Dorisio
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018
View PDFchevron_right
Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results
Ulrich Reineke
Journal of Nuclear Medicine, 2021
View PDFchevron_right
Individualized dosimetry-based activity reduction of 90Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy
Sofie Van Binnebeek
European Journal of Nuclear Medicine and Molecular Imaging, 2014
View PDFchevron_right
The role of baseline Ga-68 DOTATATE positron emission tomography/computed tomography in the prediction of response to fixed-dose peptide receptor radionuclide therapy with Lu-177 DOTATATE*
Kemal Metin Kir
TURKISH JOURNAL OF MEDICAL SCIENCES, 2016
View PDFchevron_right
Radiopharmaceutical dosimetry in targeted radionuclide therapy
Erick Mora Ramirez
2019
View PDFchevron_right
Calculation of absorbed dose due to the 90Y-DOTATOC peptide receptor radionuclide therapy by MCNP5/X
Dragoslav Nikezic
Nuclear Technology and Radiation Protection, 2018
View PDFchevron_right
Uncertainty propagation for SPECT/CT-based renal dosimetry in177Lu peptide receptor radionuclide therapy
Maurice Cox
Physics in Medicine and Biology, 2015
View PDFchevron_right
Radio-immunotherapy dosimetry with special emphasis on SPECT quantification and extracorporeal immuno-adsorption
Michael Ljungberg
Medical & Biological Engineering & Computing, 1994
View PDFchevron_right
Dosimetric characterization of radionuclides for systemic tumor therapy: Influence of particle range, photon emission, and subcellular distribution
Peter Bernhardt
Medical Physics, 2006
View PDFchevron_right
Dose response of pancreatic neuroendocrine tumours treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE
Mattias Sandström
View PDFchevron_right
Physical and chemical properties of radionuclide therapy
Barry Wessels
Seminars in Radiation Oncology, 2000
View PDFchevron_right
Biokinetics and dosimetry in patients administered with 111 In-DOTA-Tyr 3 -octreotide: implications for internal radiotherapy with 90 Y-DOTATOC
Helmut Maecke
European Journal of Nuclear Medicine and Molecular Imaging, 1999
View PDFchevron_right